Gomez E C, Menendez L, Frost P
J Am Acad Dermatol. 1979 Dec;1(6):531-7. doi: 10.1016/s0190-9622(79)80097-3.
The efficacy of orally administered mycophenolic acid (MPA), an inhibitor of guanosine monophosphate (GMP) synthesis, for the treatment of psoriasis, was studied in a double-blind fashion. Of twenty-one patients completing the study period, ten of eleven patients treated with MPA had a greater than 25% decrease in severity score compared with only two of ten patients treated with placebo. The placebo group had a slight increase in severity score compared to almost 50% reduction in the average severity score of the MPA-treated group. After termination of the double-blind portion of the study, the placebo group was treated with MPA and showed a 60% decrease in severity score. Adverse effects encountered included anorexia, nausea, vomiting, and diarrhea. One patient had an uncomplicated episode of herpes zoster. Other than a mild decrease hemoglobin, no hematologic toxicity was noted.
以双盲方式研究了口服鸟苷单磷酸（GMP）合成抑制剂霉酚酸（MPA）治疗银屑病的疗效。在完成研究期的21名患者中，接受MPA治疗的11名患者中有10名的严重程度评分下降超过25%，而接受安慰剂治疗的10名患者中只有2名出现这种情况。与MPA治疗组平均严重程度评分下降近50%相比，安慰剂组的严重程度评分略有增加。在研究的双盲部分结束后，安慰剂组接受MPA治疗，严重程度评分下降了60%。遇到的不良反应包括厌食、恶心、呕吐和腹泻。一名患者发生了一次无并发症的带状疱疹。除血红蛋白轻度下降外，未观察到血液学毒性。
